Zeo ScientifiX

Website

Zeo ScientifiX, Inc.

2 Investors
Biopharmaceutical Therapeutics
DAVIE, FL

Zeo ScientifiX, Inc., formerly known as Organicell Regenerative Medicine, Inc., is a publicly traded, clinical-stage biopharmaceutical company. It focuses on researching, developing, and manufacturing biological therapeutics derived from perinatal sources to treat degenerative diseases and support regenerative medicine applications.

Products & Team

Zofin

Clinical-Stage TherapeuticSeed

Zofin is the company's lead clinical candidate, an acellular biologic therapeutic formulated from perinatal sources. It is currently advancing through Phase I/II clinical trials for its potential to treat conditions such as COVID-19, chronic obstructive pulmonary disease (COPD), and knee osteoarthritis.

Value Proposition

Zofin is being developed to address significant unmet medical needs in degenerative and inflammatory diseases by providing a novel therapeutic option.

Pain Points

Zeo ScientifiX addresses the need for effective treatments for degenerative conditions like COPD and osteoarthritis, advanced solutions for wound care and pain management, and innovative, science-backed products for aesthetic procedures and sexual health.

Acellular biologic therapeuticDerived from perinatal sourcesCurrently in Phase I/II clinical trials
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
DAVIE, FL
Primary headquarters

Funding History

Total Raised:
$500.0K
E

Equity, Option to Acquire Offering

November 2025
$5.0M
Target
Progress
10%
Raised
$500.0K
Target
$5.0M
#000182912625009746